Compare OMER & STKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMER | STKL |
|---|---|---|
| Founded | 1994 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.8M | 769.4M |
| IPO Year | 2008 | 1999 |
| Metric | OMER | STKL |
|---|---|---|
| Price | $11.36 | $6.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.50 | $7.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 98.15 | ★ 186.67 |
| EPS | N/A | ★ 0.13 |
| Revenue | $29,868,000.00 | ★ $817,715,000.00 |
| Revenue This Year | N/A | $6.84 |
| Revenue Next Year | $165.26 | $33.58 |
| P/E Ratio | ★ N/A | $49.85 |
| Revenue Growth | N/A | ★ 12.99 |
| 52 Week Low | $2.95 | $3.32 |
| 52 Week High | $17.65 | $6.94 |
| Indicator | OMER | STKL |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 68.41 |
| Support Level | $10.82 | $6.43 |
| Resistance Level | $11.93 | $6.52 |
| Average True Range (ATR) | 0.64 | 0.02 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 47.99 | 41.67 |
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own proprietary brands, including SOWN, Dream, and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut, and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada, and Others, out of which it derives maximum revenue from U.S.